Tag: Darmstadt

Poster-Quality of Life and Outcomes

Improving Communication about Multiple Sclerosis: The MS-Support Decision Aid

Background: Good communication between patients and their health care provider (HCP) is essential for shared decision making (SDM). We...

Read More

Poster-Quality of Life and Outcomes

Assessing Presence of MS-Related Symptoms As a Proxy for Disease Severity in Multiple Sclerosis Using Administrative Claims Data

Background: Healthcare claims data lack clinically relevant variables such as disease severity. Objectives: Assess multiple sclerosis...

Read More

Poster-Quality of Life and Outcomes

Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis

Background: Historically, there has been limited research on care partners of patients with multiple sclerosis (MS). Employers, health care...

Read More

Poster-Neuroimmunology and disease models

Comparing Infection-Related Outcomes By Sex in Patients with Multiple Sclerosis and Matched Controls Using Administrative Claims Data

Background: Few population-level sex-based risk estimates of specific infections exist for US patients with multiple sclerosis (MS)....

Read More

Poster-Non-imaging Biomarkers

Concentration of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Cerebrospinal Fluid during Treatment of Patients with Relapsing Multiple Sclerosis in a Phase 2 Study

Background: Evobrutinib, a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated a low annualized relapse rate (75mg...

Read More

Poster-Non-imaging Biomarkers

The Effect of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, on Blood Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis

Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor targeting B cells and myeloid cells. A phase 2 randomized...

Read More

Poster-Disease-modifying Therapy

Classic-MS: Long-Term Efficacy and Real-World Treatment Patterns for Patients with Relapsing Multiple Sclerosis Who Received Cladribine Tablets in Phase III Parent Trials

Background: CLASSIC-MS (NCT03961204) explores the long-term efficacy and durability of effect of cladribine tablets (CladT; cumulative dose...

Read More

Poster-Disease-modifying Therapy

Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study

Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...

Read More

Poster-Disease-modifying Therapy

Clinical Outcomes in Patients with COVID-19 Infection during Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis

Background: The COVID-19 pandemic has become a significant concern for patients with multiple sclerosis (MS) and their healthcare...

Read More

Poster-Disease-modifying Therapy

Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19

Background: Several integrated analyses have reported on the safety of cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years...

Read More